Surface Oncology lays off 20% as biotech halts CD39 work on one of its ‘crown jewels’

Surface Oncology is letting go of 20% of its workforce as the biotech prunes its pipeline and narrows the scope of its lead drug.

The Boston-area cancer drug developer is looking for external partners on its CD39 asset, dubbed SRF617, after a strategic review, which the company said would extend...

Click to view original post